Primary study · included by 1 review
Preparation and clinical evaluation of a novel lozenge containing polaprezinc, a zinc-L-carnosine, for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapy.
Hayashi 2016 · Hayashi Hiroko, Kobayashi Ryo, Suzuki Akio, et al. · Medical oncology (Northwood, London, England) · 2016
Included by
| Outcome this study informs | Pooled effect | Evidence | Certainty |
|---|---|---|---|
Oral mucositis (grade >= 2), incidence Zinc L-carnosine (polaprezinc) in any formulation (mouthwash, lozenge, mucoadhesive suspension) vs Standard oral care, no prophylaxis, azulene gargle, sodium bicarbonate mouthwash or delayed ZnC | OR 0.56 [0.33, 0.95] | 4 studies · 335 participants | Low |
Oral mucositis (grade >= 2), incidence Zinc L-carnosine (polaprezinc) in any formulation (mouthwash, lozenge, mucoadhesive suspension) vs Standard oral care, no prophylaxis, azulene gargle, sodium bicarbonate mouthwash or delayed ZnC | OR 0.36 [0.10, 1.29] | 4 studies · 335 participants | Low |
Severe oral mucositis (grade >= 3), incidence Zinc L-carnosine (polaprezinc) in any formulation (mouthwash, lozenge, mucoadhesive suspension) vs Standard oral care, no prophylaxis, azulene gargle, sodium bicarbonate mouthwash or delayed ZnC | OR 0.44 [0.18, 1.06] | 7 studies · 532 participants | Low |
Severe oral mucositis (grade >= 3), incidence Zinc L-carnosine (polaprezinc) in any formulation (mouthwash, lozenge, mucoadhesive suspension) vs Standard oral care, no prophylaxis, azulene gargle, sodium bicarbonate mouthwash or delayed ZnC | OR 0.48 [0.32, 0.72] | 7 studies · 532 participants | Low |
1 including review in total.